

Subcutaneous Immunoglobulin (SCIG) | Order Form

Patient Name: _____ DOB: _____ Phone: _____
 Address: _____ City: _____ State: _____ Zip: _____

1. For new patients, please submit with form:

- Copy of insurance card Demographics History & physical Labs Testing results supporting diagnosis
 Baseline assessment (include medications tried and failed if any)

2. Patient Information

Male Female Height: _____ in/cm Weight: _____ lbs/kg Allergies: _____

History of immunoglobulin (IG) therapy:

- New to IG therapy Continuing on SCIG Switching from IVIG to SCIG*. Current IVIG product/dose/frequency: _____
 *Note: SCIG will begin 1 week after final dose of IVIG if possible, unless otherwise specified by prescriber
 Date of final IVIG infusion before switching to SCIG: _____ Date desired for first SCIG infusion: _____

3. Diagnosis and Clinical Information

ICD-10 (required): _____

- Primary diagnosis: Congenital hypogammaglobulinemia CVID SCID CIDP Multifocal motor neuropathy Multiple sclerosis
 Guillain-barré syndrome Myasthenia gravis Polymyositis Dermatomyositis Other _____

4. Prescription Information

SCIG Product	<input checked="" type="checkbox"/> SCIG: pharmacist to select product based on patient specific factors and notify provider of selection <input type="checkbox"/> Specific SCIG product required (list product): _____
Loading Dose	IVIG – Product: <input type="checkbox"/> Unbranded (pharmacist to select product) or <input type="checkbox"/> Brand required: _____ Administer _____ grams OR _____ grams/kg* IV divided over _____ day(s) one time Other: _____
Maintenance SCIG Dose	Dose: _____ grams OR _____ grams/kg* (rounded to nearest whole vial size) <input type="checkbox"/> *If weight is >130% ideal body weight (IBW), use adjusted body weight (IBW+0.4[ABW-IBW]) to calculate dose Frequency: <input type="checkbox"/> Weekly <input type="checkbox"/> Every 2 weeks <input type="checkbox"/> Other: _____
SCIG Administration	<input checked="" type="checkbox"/> Infuse subcutaneously via infusion pump, using 1 or more sites, adjusted as tolerated per manufacturer guidelines OR infuse in _____ site(s) using _____ rate flow tubing over _____ minutes <input type="checkbox"/> Other: _____
Quantity / Refills	Dispense 1 month supply / Refill x 12 months <input type="checkbox"/> Other: _____ Dispense all medical supplies necessary for infusion

5. Additional Orders

- For IV loading dose (if ordered): RN to start peripheral IV or existing CVC. RN to administer catheter flushing per PromptCare Policy and Procedure
 RN may instruct patient to hydrate pre/post infusion and educate on taking **OTC diphenhydramine and/or acetaminophen** per manufacturer dosing recommendations as needed to prevent/treat post-infusion headache.
 Skilled nursing services to be provided for infusion, assessment and teaching of SCIG as needed
 Other: _____

6. Adverse Reaction Orders

- For SCIG: Prescriber to send separate prescription to retail pharmacy of patient's choice for epinephrine pen, for use in anaphylactic reaction
 For IVIG **only**: Standard anaphylaxis kit to be dispensed and dosed per protocol: Epinephrine IM/SQ (1 mg/mL vial), diphenhydramine IV/IM (50 mg/mL vial), and NS IV

7. Prescriber Information

Address: _____ City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____
 License No.: _____ DEA NO.: _____ NPI: _____

Physician Signature (Substitution Permitted)

Date

Physician Signature (Dispense as Written)

Date

By signing I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment. PromptCare has my permission to contact the patient's health plan to obtain any authorizations necessary to enable it to receive payment for services.

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.